Shares of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX - Get Free Report) traded up 6.6% during mid-day trading on Thursday . The stock traded as high as $1.42 and last traded at $1.38. 1,868,052 shares were traded during trading, a decline of 73% from the average session volume of 6,856,816 shares. The stock had previously closed at $1.29.
Analyst Ratings Changes
Several equities research analysts have recently issued reports on the stock. Wall Street Zen assumed coverage on shares of Lexicon Pharmaceuticals in a research report on Monday, April 21st. They set a "sell" rating for the company. HC Wainwright reissued a "buy" rating and set a $4.00 price objective on shares of Lexicon Pharmaceuticals in a research report on Tuesday, June 24th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and two have given a buy rating to the company's stock. Based on data from MarketBeat, Lexicon Pharmaceuticals currently has an average rating of "Hold" and a consensus price target of $3.67.
Get Our Latest Stock Analysis on Lexicon Pharmaceuticals
Lexicon Pharmaceuticals Trading Up 4.7%
The firm has a market cap of $488.01 million, a P/E ratio of -2.65 and a beta of 1.13. The business's 50-day moving average is $0.77 and its two-hundred day moving average is $0.67. The company has a debt-to-equity ratio of 0.48, a current ratio of 2.22 and a quick ratio of 2.22.
Lexicon Pharmaceuticals (NASDAQ:LXRX - Get Free Report) last announced its quarterly earnings data on Tuesday, May 13th. The biopharmaceutical company reported ($0.07) EPS for the quarter, beating analysts' consensus estimates of ($0.10) by $0.03. Lexicon Pharmaceuticals had a negative net margin of 568.04% and a negative return on equity of 103.16%. The company had revenue of $1.26 million during the quarter, compared to the consensus estimate of $1.26 million. As a group, analysts predict that Lexicon Pharmaceuticals, Inc. will post -0.66 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently modified their holdings of the company. Wellington Management Group LLP grew its position in shares of Lexicon Pharmaceuticals by 2.1% in the 4th quarter. Wellington Management Group LLP now owns 747,996 shares of the biopharmaceutical company's stock valued at $552,000 after acquiring an additional 15,249 shares during the period. Teacher Retirement System of Texas boosted its holdings in shares of Lexicon Pharmaceuticals by 60.3% during the 4th quarter. Teacher Retirement System of Texas now owns 65,415 shares of the biopharmaceutical company's stock worth $48,000 after buying an additional 24,615 shares during the period. Bank of America Corp DE boosted its holdings in shares of Lexicon Pharmaceuticals by 27.4% during the 4th quarter. Bank of America Corp DE now owns 136,407 shares of the biopharmaceutical company's stock worth $101,000 after buying an additional 29,319 shares during the period. Invesco Ltd. boosted its holdings in shares of Lexicon Pharmaceuticals by 60.6% during the 4th quarter. Invesco Ltd. now owns 104,494 shares of the biopharmaceutical company's stock worth $77,000 after buying an additional 39,420 shares during the period. Finally, Bayesian Capital Management LP bought a new stake in shares of Lexicon Pharmaceuticals during the 4th quarter worth about $31,000. Institutional investors own 74.70% of the company's stock.
About Lexicon Pharmaceuticals
(
Get Free Report)
Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Lexicon Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Lexicon Pharmaceuticals wasn't on the list.
While Lexicon Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
